Abstract
A sensitive and convenient method for the detection of epidermal growth factor receptor (EGFR) T790M mutation in non-small cell lung cancer (NSCLC) patients with acquired resistance to tyrosine kinase inhibitors (TKIs) would be desirable to guide treatment strategy. Consequently, studies have focused on sensitive characterization of EGFR T790M mutation. Herein, two methods of co-amplification at lower denaturation temperature PCR (COLD-PCR) and pyrosequencing were combined (COLDPCR/ pyrosequencing) for detecting EGFR T790M mutation. Evaluation of mutation-containing dilutions revealed that the sensitivities of COLD-PCR/pyrosequencing and conventional PCR/pyrosequencing assays for the detection of the T790M mutation were 0.1 and 5%, respectively, indicating a 50-fold increase in sensitivity. When the T790M mutation in 20 clinical NSCLC samples who had relapsed under firstgeneration EGFR TKI were further determined using COLD-PCR/pyrosequencing and conventional PCR/pyrosequencing, the detection rates were 35% (7/20) and 25% (5/20), respectively. All patients who were positive for the T790M mutation with conventional PCR/pyrosequencing were also found to be positive with COLD-PCR/pyrosequencing. The discordant cases were 2 samples with no T790M mutation detected with conventional PCR/pyrosequencing, but which were positive with COLD-PCR/pyrosequencing. COLD-PCR/pyrosequencing is a sensitive and cost-effective tool for detecting the T790M mutation which will permit an improvement of therapeutic management.
Highlights
In recent years, the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the survival of patients with nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations ([1])
highresolution melting (HRM) is a simple, rapid and sensitive method for detecting EGFR T790M mutation, it is hampered by the inability to identify the specific nucleotide change ([10])
We demonstrate that upstream COLD-PCR assay allows for the enrichment of EGFR T790M mutation in a sensitive and inexpensive manner and downstream pyrosequencing of COLD-CPR products allows for the discrete identification of low-abundance EGFR T790M mutation
Summary
The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has significantly improved the survival of patients with nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations ([1]). The current methods for detecting of T790M mutation in clinical practice include real-time PCR assays ([4]), allele-specific (AS) PCR ([5]), amplification refractory mutation system (ARMS) ([1]), droplet digital PCR (ddPCR) ([1, 5]), highresolution melting (HRM) ([6]), Sanger sequencing ([6]) and next-generation sequencing (NGS) ([7]). Among those PCR-based methods, some do not allow to detect low-abundance EGFR T790M mutation, while others are highly sensitive. Finding a sensitive and convenient detection assay is important
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.